symptoms of glp 1 How Do You Know When Semaglutide GLP-1 Is Working? Managing symptoms with GLP-1 receptor

Where to inject: Choose any spot at least two inches from your belly button

Today, you can also take prescription medications called GLP-1 receptor agonists, such as Ozempic (indicated to treat diabetes) and Wegovy (indicated for weight loss)

Convenient & Easy to Use The liquid format makes dosing simple and flexible, without the need to swallow pills or capsules

Obesity affects male fertility as well, and metabolic optimisation may become part of fertility planning for both partners

Cancer (active diagnosis or treatment) 7

Approval Timeline and Availability CagriSema: Ahead in the Race FDA Submission: December 18, 2025 (NDA filed) Expected FDA Decision: Q4 2026 or Q1 2027 Predicted Launch: Mid-2027 Advantage: 6-12 month head start on retatrutide REDEFINE Program Status: REDEFINE-1: Completed (obesity, 20.4% weight loss) REDEFINE-2: Completed (type 2 diabetes, 13.7% weight loss) REDEFINE-3: Ongoing (cardiovascular outcomes trial) REDEFINE-8: Ongoing (body composition study) High-dose CagriSema (2.4/7.2mg): Starting late 2026 Retatrutide: More Trials Needed FDA Submission: Expected Q4 2026 or Q1 2027 Expected FDA Decision: Late 2027 Predicted Launch: Q1-Q2 2028 TRIUMPH Program Status: TRIUMPH-4: Completed (osteoarthritis, 28.7% weight loss) TRIUMPH-1: Complete 28.3% weight loss (May 2026) TRIUMPH-2: Expected Q3Q4 2026 (obesity + type 2 diabetes) TRIUMPH-3: Expected later 2026 (obesity + cardiovascular disease) TRIUMPH-6: Weight maintenance trial (ongoing) Disadvantage: Needs more trials before submission, 6-12 month delay vs CagriSema